Memorandum Date: To: For: From: Subject: April 11‚ 2013 Jay Jenlink‚ Regional Vice President Securities Licensing Recruits Joshua Conaway‚ Sales Representative Getting Licensed to Increase Business with Primerica There are many business opportunities in Primerica Financial Services. One of the greatest opportunities is receiving residual income by helping clients with investing for their future. It is rewarding in knowing that you are helping your clients’ future financial status as well as getting
Premium Financial services Internet Explorer License
Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new drug with the potential to
Premium Patent Pharmacology Pharmaceutical drug
TO: Dr. Roy Vagelos‚ Chairman and CEO Merck Corporation. January‚ 1991. The decision to move forward with the program to donate the new drug Mectizan on a large scale to the affected population in the Third World needs to be systematically analyzed. There are two especially important angles from which this decision needs to be considered. The first concern that needs to be taken into account is that of the stockholders and investors in this company‚ whose interests you are ultimately charged with
Premium Medicine Pharmacology Pharmacy
a) Introduction in 1999 b) Withdrawal of the drug in 2004 due to heart attacks c) Merck’s knowledge of the effects of Vioxx and unethical decision to continue to sell the drug 2) Vigor Study d) Vioxx lessened stomach bleeding e) Results also showed higher risk of heart attacks f) Merck blamed naproxen for skewing the results against Vioxx 3) New England Journal of Medicine Omission g) Merck omits three heart attacks from article submission
Premium Coronary artery disease Aspirin Hypertension
Merck SWOT Analysis MGT/521 July 25‚ 2012 Merck SWOT Analysis Company Overview Merck is the 2nd largest pharmaceutical company in world offering prescription medications‚ biologics‚ vaccines‚ animal health‚ and consumer care products. It generated 48 billion dollars in revenue in 2011 and has 40‚000 employees. Research and development of proprietary medicines for global marketing is the core of the business. Recent acquisitions and transactions designed to take advantage
Premium Management Strategic management Marketing
Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next‚ if Merck decides to pursue license‚ they go into phase I which results in a success‚ or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone‚ weight loss alone‚ or both‚ or contemplate phase II failure. Finally phase
Premium Decision tree Decision theory
including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business‚ as they seek to gain scale in a fragmented industry‚ according to several people familiar with the matter. Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit‚ best known for Coppertone sunscreen and Claritin allergy medicine‚ the sources said this week. The Merck business‚ which also includes Dr. Scholl’s foot
Premium Pharmacology Marketing Pharmacy
Licensing * Permission Granted * Legal Considerations involved in developing a sport/event licensing program * Procedures for developing a sport/event licensing program * Why learn how to develop a sport/event licensing program * 1. Every licensed product= a detailed license agreement * 2. Important to develop and maintain licensing systems carefully * 3. Essential for anyone interested in the field to learn the basics of developing a licensing system
Premium Trademark License
c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money
Merck and Co. and river blindness MANUEL VELASQUEZ‚ Business Ethics. Concepts and cases 4th edt.‚ Prentice Hall‚ Upper Saddle River‚ New Jersey‚ 1998 River blindness is an agonizing disease that affects some 18 million impoverished people living in remote villages along the banks of rivers in tropical regions of Africa and Latin America. The disease is caused by a tiny parasitic worm that is passed from person to person by the bite of the black fly which breeds in river waters. The tiny worms
Premium Pharmaceutical industry Ethics Drug discovery